Bharat Biotech and Alopexx Partner to Combat Covid-19 and Bacterial Infections

Wednesday, 11 September 2024, 01:41

Bharat Biotech has partnered with Alopexx to develop an anti-microbial vaccine aimed at combating bacterial infections and addressing Covid-19. This collaboration focuses on creating affordable vaccination solutions for low-income countries. The co-development of AV0328 seeks to reduce anti-microbial resistance worldwide.
LivaRava_Medicine_Default.png
Bharat Biotech and Alopexx Partner to Combat Covid-19 and Bacterial Infections

Bharat Biotech has announced a collaboration with Alopexx Inc for the development and commercialisation of AV0328, a broad-spectrum anti-microbial vaccine. This vaccine aims to provide solutions for bacterial infections and is particularly focused on low-and middle-income countries.

Collaboration Details

As part of the agreement, Bharat Biotech will co-develop and commercialise the vaccine in India and other licensed territories. Alopexx will receive an upfront payment along with milestone payments and royalties based on future sales.

Importance of Anti-Microbial Solutions

  • Krishna Ella, Executive Chairman of Bharat Biotech, stated the goal is to reduce anti-microbial resistance through vaccination efforts.
  • CEO of Alopexx, Daniel Vlock, emphasized the critical need for affordable antimicrobial solutions, especially in low-income regions.

Clinical Trials and Safety

A phase I trial for AV0328 has been successfully completed, showing it is well-tolerated without serious adverse events.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe